Patients carrying this variant are predicted to experience a gain-of-function (GOF) (rs117793540) and the hyperactivation of C3 through the alternative C3-convertase pathway, disrupting the anaphylatoxin-mediated response to infection. The gene discussed is C3; the disease is infection.